↓ Skip to main content
What is this page? Embed badge

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro…

Overview of attention for article published in Tumori Journal, November 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#25 of 968)
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
18 X users

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
27 Mendeley
Summary X Dimensions citations
So far, Dimensions has found 19 publications that cite this research output.

19

The most recent citing publications are shown below. View all 19 publications that cite this research output on Dimensions.

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.

This page is provided by Altmetric.